睿知中国医院研究地图
候选清单

福州福建医科大学

福建省肿瘤医院

Fujian Cancer Hospital

在本站收录的 53 种疾病中,这家医院列在其中 7 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

福建省肿瘤医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma87 篇牵头论文牵头 5 项开放试验
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma32 篇牵头论文牵头 1 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma54 篇牵头论文
  4. 胃癌Stomach cancer38 篇牵头论文牵头 4 项开放试验
  5. 肝母细胞瘤Hepatoblastoma1 篇牵头论文
  6. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  7. 神经母细胞瘤Neuroblastoma1 篇牵头论文

未列出的收录疾病:视网膜母细胞瘤、脊索瘤、骨肉瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 87 篇,占 3.7%。

牵头论文
87
2021–2025 年
牵头试验
16
任何状态,ClinicalTrials.gov
牵头的开放试验
5
正在或即将招募
作为研究中心的开放试验
14
由其他机构牵头
每年牵头的论文数
2021: 101020212022: 101020222023: 212120232024: 212120242025: 24242025

福州有 5 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 19

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC
    分期
    II期
    开始
    2026-06
    登记号
    NCT07331428

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:福建省肿瘤医院福州

  2. 正在招募
    IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features
    分期
    未注明
    开始
    2026-01
    登记号
    NCT07376603

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:福建省肿瘤医院福州

  3. 正在招募
    CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2025-01
    登记号
    NCT06095154

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:福建省肿瘤医院福州

  4. 即将招募
    Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2026-01
    登记号
    NCT07268690

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:福建省肿瘤医院福州

  5. 即将招募
    Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC
    分期
    III期
    开始
    2024-01
    登记号
    NCT06095167

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:福建省肿瘤医院福州

  6. 正在招募
    PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
    分期
    III期
    开始
    2026-04
    登记号
    NCT07235319

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 4 家列出的医院为研究中心南宁、广州、杭州、福州、长沙

  7. 正在招募
    Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
    分期
    II期
    开始
    2026-07
    登记号
    NCT07528183

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 3 家列出的医院为研究中心南宁、广州、武汉、福州

  8. 正在招募
    Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2026-09
    登记号
    NCT07796789

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 2 家列出的医院为研究中心广州、福州、长沙

  9. 正在招募
    QL1706(PD-1/CTLA-4 双特异性抗体)联合放化疗用于局部区域晚期鼻咽癌QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    分期
    III期
    开始
    2025-05
    登记号
    NCT06749899

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 17 家列出的医院为研究中心上海、东莞、中山、佛山、南京、南宁、厦门、天津、广州、成都、武汉、福州、贵阳、长沙

  10. 正在招募
    A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
    分期
    II期
    开始
    2025-04
    登记号
    NCT06839066

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心东莞、中山、南宁、广州、成都、杭州、武汉、深圳、福州、赣州、长沙

  11. 正在招募
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
    分期
    I/II期
    开始
    2025-11
    登记号
    NCT07258979

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、东莞、南宁、南昌、厦门、广州、成都、昆明、杭州、桂林、江门、海口、福州、重庆、长沙、韶关

  12. 正在招募
    喉咽清口服液防治鼻咽癌放射性口腔黏膜炎Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
    分期
    III期
    开始
    2025-12
    登记号
    NCT07311772

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、北京、南宁、常州、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙

  13. 正在招募
    40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2025-11
    登记号
    NCT07328854

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心中山、南宁、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙

  14. 正在招募
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    分期
    II期
    开始
    2024-01
    登记号
    NCT05956587

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心临沂、南昌、天津、广州、杭州、柳州、武汉、福州、西安、郑州、重庆

  15. 正在招募
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    分期
    III期
    开始
    2024-03
    登记号
    NCT06239727

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 21 家列出的医院为研究中心东莞、佛山、南京、南宁、南昌、厦门、天津、广州、成都、杭州、武汉、汕头、海口、湛江、福州、西安、贵阳、重庆、长沙

  16. 正在招募
    Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
    分期
    未注明
    开始
    2024-05
    登记号
    NCT06445088

    年龄未注明(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 4 家列出的医院为研究中心中山、南宁、广州、梧州、福州

  17. 正在招募
    Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
    分期
    不分期
    开始
    2023-06
    登记号
    NCT05892354

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:广西医科大学第一附属医院;另有 13 家列出的医院为研究中心南宁、南昌、广州、杭州、柳州、桂林、梧州、海口、福州

  18. 正在招募
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
    分期
    III期
    开始
    2022-04
    登记号
    NCT05340491

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 10 家列出的医院为研究中心上海、南宁、南昌、厦门、广州、成都、杭州、武汉、福州、西安、贵阳

  19. 正在招募
    PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
    分期
    III期
    开始
    2020-03
    登记号
    NCT03907826

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 10 家列出的医院为研究中心上海、南宁、南昌、厦门、广州、成都、杭州、武汉、福州、西安、贵阳

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。

这些数字背后的记录
研究主题放疗技术复发与转移影像与人工智能
论文中的科室放疗科肿瘤内科影像/核医学科耳鼻喉/头颈外科
牵头的论文87
  1. Appraisal of Radiologic Size Criteria for Malignant Lymph Nodes in Parotid Region in Nasopharyngeal Carcinoma: Implication for Parotid-Sparing IMRT.2026Head & neck
  2. Watch-and-wait strategy in patients with objective response after immuno-chemotherapy for locally recurrent nasopharyngeal carcinoma: a pilot study.2025BMC cancer免费全文
  3. The prognostic value of boost dose in residual cervical lymph nodes in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy: a retrospective study.2025BMC cancer免费全文
  4. Prognostic implications of EBER and EBV DNA combinations in nasopharyngeal carcinoma in endemic areas.2025BMC oral health免费全文
  5. Prognostic Value of Pre-Treatment Diffusion Kurtosis Imaging for Progression-Free Survival Prediction in Advanced Nasopharyngeal Carcinoma.2025Cancer medicine免费全文
  6. Deep learning MRI-based radiomic models for predicting recurrence in locally advanced nasopharyngeal carcinoma after neoadjuvant chemoradiotherapy: a multi-center study.2025Clinical & experimental metastasis免费全文
  7. Comparative evaluation of machine learning models in predicting overall survival for nasopharyngeal carcinoma using 18F-FDG PET-CT parameters.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  8. Insights into the Prognostic Efficacy of the Geriatric Nutritional Risk Index for Nasopharyngeal Carcinoma in the Era of Volumetric Modulated Arc Therapy: A Nomogram for Predicting Long-Term Survival Outcomes.2025Current oncology (Toronto, Ont.)免费全文
  9. Validation and development of a refined M1 category for nasopharyngeal carcinoma based on the version-nine of AJCC/UICC TNM staging system in the immunotherapy era: A multicenter cohort study.2025European journal of cancer (Oxford, England : 1990)
  10. PSPC1 knockout promotes radiosensitivity, inhibits EMT, and metastasis of nasopharyngeal carcinoma cells.2025Experimental cell research
  11. The key role of DLX6 in nasopharyngeal carcinoma: metastasis, angiogenesis and tumor immune mechanism.2025Frontiers in immunology免费全文
  12. PAK6 drives tumor microenvironment remodeling in nasopharyngeal carcinoma with lymph node necrosis: implications for distant metastasis and survival.2025International immunopharmacology
  13. SPP1-mediated M2 macrophage polarization shapes the tumor microenvironment and enhances prognosis and immunotherapy guidance in nasopharyngeal carcinoma.2025International immunopharmacology
  14. Treatment outcomes in nasopharyngeal carcinoma patients with parotid lymph node metastasis: An 11-year experience at a tertiary cancer center.2025International journal of cancer
  15. International Consensus Guideline on Delineation of the Clinical Target Volumes at Different Dose Levels for Nasopharyngeal Carcinoma (2024 Version).2025International journal of radiation oncology, biology, physics
  16. Plasma Epstein-Barr Virus DNA Temporal Clearance Pattern During Induction-Concurrent (Chemo)Radiation Therapy for Risk Stratification in Nasopharyngeal Carcinoma.2025International journal of radiation oncology, biology, physics
  17. Long-Term Outcome in Cervical Lymph Node-Positive Nasopharyngeal Carcinoma Following Intensity Modulated Radiation Therapy With One-Step Cervical Nodal Clinical Target Volume Delineation by Geometric-Anatomic Expansion From Nodal Gross Targ2025International journal of radiation oncology, biology, physics
  18. Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival.2025JCO precision oncology免费全文
  19. PXDN regulated by WTAP/YTHDF1-mediated m6A modification activates PI3K/AKT signaling pathway through extracellular matrix remodeling to promote progression in nasopharyngeal carcinoma.2025Journal of experimental & clinical cancer research : CR免费全文
  20. Utilization of 18F-FDG Standardized Uptake Value and Metabolic Tumor Volume to Predict Local Failure in Nasopharyngeal Carcinoma.2025Oncology
  21. A nomogram integrating clinical stage and pre-EBV DNA to identify the cycles of induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma.2025Radiation oncology (London, England)免费全文
  22. Transforming the management of radiotherapy-induced hypothyroidism in nasopharyngeal carcinoma through an Innovative individualized radiation dosage model: A multicenter retrospective analysis.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  23. Identifying adverse nodal features associated with poor prognosis in stage IB nasopharyngeal carcinoma patients based on the 9th AJCC/UICC staging system: Implications for treatment intensification.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  24. Consistency evaluation and performance optimization of deep learning-based auto-contouring for nasopharyngeal carcinoma.2025Scientific reports免费全文
  25. Systemic immune-inflammation index and serum lactate dehydrogenase predict the prognosis of non-metastatic nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy.2025Scientific reports免费全文
  26. Role of PET/CT in improving the cost effectiveness of nimotuzumab in nasopharyngeal carcinoma.2024Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale免费全文
  27. Impact of the radiotherapy rhythm on prognosis in nasopharyngeal carcinoma.2024Annals of medicine免费全文
  28. A nomogram based on nutritional and inflammatory parameters to predict DMFS and identify beneficiaries of adjuvant chemotherapy in IVA-stage nasopharyngeal carcinoma.2024BMC cancer免费全文
  29. Efficacy of salvage surgery versus re-irradiation for isolated regional lymph node recurrence in patients with nasopharyngeal carcinoma.2024BMC cancer免费全文
  30. Significance of radiologic extranodal extension in locoregionally advanced nasopharyngeal carcinoma with lymph node metastasis: a comprehensive nomogram.2024Brazilian journal of otorhinolaryngology免费全文
  31. Identification of novel molecular subtypes to improve the classification framework of nasopharyngeal carcinoma.2024British journal of cancer免费全文
  32. Establishment and validation of circulating cell-free DNA signatures for nasopharyngeal carcinoma detection.2024EBioMedicine免费全文
  33. 5-Hydroxymethylcytosines in circulating cell-free DNA as a diagnostic biomarker for nasopharyngeal carcinoma.2024European journal of cancer (Oxford, England : 1990)
  34. m6A methylation profiling as a prognostic marker in nasopharyngeal carcinoma: insights from MeRIP-Seq and RNA-Seq.2024Frontiers in immunology免费全文
  35. Early recurrence as a pivotal event in nasopharyngeal carcinoma: identifying predictors and key molecular signals for survivors.2024Head & face medicine免费全文
  36. Intratumoral habitat radiomics based on magnetic resonance imaging for preoperative prediction treatment response to neoadjuvant chemotherapy in nasopharyngeal carcinoma.2024Japanese journal of radiology
  37. Individualized radiology screening for newly diagnosed nasopharyngeal carcinoma.2024Oral oncology
  38. Selectively sparing of the supraclavicular area during intensity-modulated radiotherapy in nasopharyngeal carcinoma: A double-center observation study.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  39. Multifactorial clinical analysis of factors affecting necrosis of nasal septal mucosal flap after salvage surgery for recurrent nasopharyngeal carcinoma.2024Scientific reports免费全文
  40. Selection of induction chemotherapy cycles for stage N3 nasopharyngeal carcinoma based on pre-treatment plasma EBV DNA.2024Scientific reports免费全文
  41. A scoring system based on inflammatory and nutritional indicators to predict the long-term survival of patients with non-metastatic nasopharyngeal carcinoma.2024Scientific reports免费全文
  42. Baseline SUVmax is correlated with tumor hypoxia and patient outcomes in nasopharyngeal carcinoma.2024Scientific reports免费全文
  43. Failure patterns and individualized treatment plans of reirradiation for inoperable locally recurrent nasopharyngeal carcinoma.2024Scientific reports免费全文
  44. Plasma Epstein-Barr virus microRNA BART8-3p as a potential biomarker for detection and prognostic prediction in early nasopharyngeal carcinoma.2024Scientific reports免费全文
  45. Risk-adapted locoregional radiotherapy strategies based on a prognostic nomogram for de novo metastatic nasopharyngeal carcinoma patients treated with chemoimmunotherapy.2024Scientific reports免费全文
  46. Comorbidity profiling identifies potential subtype of elderly patients with nasopharyngeal carcinoma.2024The oncologist免费全文
  47. Analysis of risk characteristics for metachronous metastasis in different period of nasopharyngeal carcinoma.2023BMC cancer免费全文
  48. The effect of primary tumor volume on the prognosis of nasopharyngeal carcinoma in era of volumetric modulated arc therapy: a propensity score matched cohort study.2023Brazilian journal of otorhinolaryngology免费全文
  49. Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy.2023Cancer research and treatment免费全文
  50. Effect of Percutaneous Endoscopic Gastrostomy on Quality of Life after Chemoradiation for Locally Advanced Nasopharyngeal Carcinoma: A Cross-Sectional Study.2023Current oncology (Toronto, Ont.)免费全文
  51. An immune-related prognostic model predicts neoplasm-immunity interactions for metastatic nasopharyngeal carcinoma.2023Frontiers in immunology免费全文
  52. Do all patients at the initial stage of nasopharyngeal carcinoma need bone metastasis screening? A retrospective study.2023Head & neck
  53. Prioritizing sufficient dose to gross tumor volume over normal tissue sparing in intensity-modulated radiotherapy treatment of T4 nasopharyngeal carcinoma.2023Head & neck
  54. Recommendation for imaging follow-up strategy based on time-specific disease failure for nasopharyngeal carcinoma.2023Head & neck
  55. Prognostic nutritional index and serum lactate dehydrogenase predict the prognosis of nasopharyngeal carcinoma patients who received intensity-modulated radiation therapy.2023Journal of cancer research and clinical oncology免费全文
  56. Significance of chemotherapy for older patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A propensity score matching analysis.2023Journal of geriatric oncology
  57. Prediction of Potential Biomarkers in Early-Stage Nasopharyngeal Carcinoma Based on Platelet RNA Sequencing.2023Molecular biotechnology免费全文
  58. Thyroid V40 is a good predictor for subclinical hypothyroidism in patients with nasopharyngeal carcinoma after intensity modulated radiation therapy: a randomized clinical trial.2023Radiation oncology (London, England)RCT免费全文
  59. Prognostic model on overall survival in elderly nasopharyngeal carcinoma patients: a recursive partitioning analysis identifying pre-treatment risk stratification.2023Radiation oncology (London, England)免费全文
  60. PET/CT standardized uptake value and EGFR expression predicts treatment failure in nasopharyngeal carcinoma.2023Radiation oncology (London, England)免费全文
  61. Biological target volume based on fluorine-18-fluorode-oxyglucose positron emission tomography/computed tomography imaging: a spurious proposition?2023Radiation oncology (London, England)免费全文
  62. Constructing an individualized surveillance framework for nasopharyngeal carcinoma based on a dynamic risk-adapted approach.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  63. Comparison the acute toxicity of two different induction chemotherapy schedules with cisplatin and fluorouracil in nasopharyngeal carcinoma patients.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRCT
  64. Radiomics-clinical nomogram based on pretreatment 18F-FDG PET-CT radiomics features for individualized prediction of local failure in nasopharyngeal carcinoma.2023Scientific reports免费全文
  65. CBCT-based synthetic CT generated using CycleGAN with HU correction for adaptive radiotherapy of nasopharyngeal carcinoma.2023Scientific reports免费全文
  66. Shifted-excitation Raman difference spectroscopy for improving in vivo detection of nasopharyngeal carcinoma.2023Talanta
  67. Impact of Radiotherapy Combined With Chemotherapy on Long-Term Outcomes of Patients With Recurrent Nasopharyngeal Carcinoma.2023Technology in cancer research & treatment免费全文
  68. Re-evaluation of the prognostic significance of retropharyngeal node metastasis in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.2022Asia-Pacific journal of clinical oncology
  69. RNF38 suppress growth and metastasis via ubiquitination of ACTN4 in nasopharyngeal carcinoma.2022BMC cancer免费全文
  70. Reflecting on the utility of standardized uptake values on 18F-FDG PET in nasopharyngeal carcinoma.2022BMC cancer免费全文
  71. Optimizing the treatment mode for de novo metastatic nasopharyngeal carcinoma with bone-only metastasis.2022BMC cancer免费全文
  72. Prognostic Relevance of Change in Body Mass Index in Patients With Nasopharyngeal Carcinoma Undergoing Volumetric Modulated Arc Therapy: A Retrospective Study.2022Cancer control : journal of the Moffitt Cancer Center免费全文
  73. Plasma Epstein-Barr viral DNA load after completion of two cycles of induction chemotherapy predicts outcomes for patients with advanced-stage nasopharyngeal carcinoma.2022Oral oncology
  74. Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma.2022Radiation oncology (London, England)免费全文
  75. Level Ib sparing intensity-modulated radiation therapy in selected nasopharyngeal carcinoma patients based on the International Guideline.2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  76. Evaluation of auto-planning in VMAT for locally advanced nasopharyngeal carcinoma.2022Scientific reports免费全文
  77. Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma.2022The oncologist免费全文
  78. Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma.2021BMC cancer免费全文
  79. Prognostic value of serum uric acid and tumor response to induction chemotherapy in locally advanced nasopharyngeal carcinoma.2021BMC cancer免费全文
  80. Prognostic models for 1-year survival of NPC after radiotherapy in different ages.2021European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  81. Identifying the optimal candidates for locoregional radiation therapy in patients with de novo metastatic nasopharyngeal carcinoma.2021Head & neck
  82. Significance of boost dose for T4 nasopharyngeal carcinoma with residual primary lesion after intensity-modulated radiotherapy.2021Journal of cancer research and clinical oncology免费全文
  83. Percutaneous endoscopic gastrostomy can improve survival outcomes in patients with N3 nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy.2021Oral oncology
  84. Administration of oral maintenance chemotherapy for 1 year following definitive chemoradiotherapy may improve the survival of patients with stage N3 nasopharyngeal carcinoma.2021Oral oncology
  85. Selectively recommend 18F-FDG PET/CT for patients with de novo nasopharyngeal carcinoma in endemic areas.2021Radiation oncology (London, England)免费全文
  86. Modified reduced-volume intensity-modulated radiation therapy in non-metastatic nasopharyngeal carcinoma: A prospective observation series.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  87. Response to Chai' letter: What caused the difference in prognosis among different physicians?2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
它在 ClinicalTrials.gov 上的全部试验(任何状态)43
  1. Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma即将招募NCT07268690牵头方III期2026-01 启动
  2. MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC正在招募NCT07331428牵头方II期2026-06 启动
  3. CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma正在招募NCT06095154牵头方III期2025-01 启动
  4. Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC即将招募NCT06095167牵头方III期2024-01 启动
  5. Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life状态不明NCT06136962牵头方2023-12 启动
  6. Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma状态不明NCT04955886牵头方II期2021-08 启动
  7. Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC状态不明NCT04745741牵头方2021-05 启动
  8. Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma状态不明NCT04319471牵头方II期2020-06 启动
  9. To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC已完成NCT04387266牵头方2020-06 启动
  10. Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC状态不明NCT04421469牵头方II期2020-06 启动
  11. Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC状态不明NCT04220528牵头方II期2019-12 启动
  12. EBV-TCR-T(YT-E001)for Patients With EBV-positive Recurrent or Metastatic NPC状态不明NCT03648697牵头方II期2018-10 启动
  13. Appaconitine Patch for Oral Mucositis Pain Caused by Chemoradiotherapy in Patients With Nasopharyngeal Cancer状态不明NCT03518489牵头方不分期2018-07 启动
  14. Nimotuzumab for Recurrent Nasopharyngeal Carcinoma状态不明NCT03666221牵头方II期2014-11 启动
  15. Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma已完成NCT02113423牵头方不分期1996-01 启动
  16. IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features正在招募NCT07376603牵头方(推断)2026-01 启动
  17. Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma正在招募NCT07528183研究中心II期2026-07 启动
  18. Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma正在招募NCT07796789研究中心III期2026-09 启动
  19. PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC正在招募NCT07235319研究中心III期2026-04 启动
  20. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid正在招募NCT07311772研究中心III期2025-12 启动
  21. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.正在招募NCT06749899研究中心III期2025-05 启动
  22. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.正在招募NCT07258979研究中心I/II期2025-11 启动
  23. 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma正在招募NCT07328854研究中心III期2025-11 启动
  24. A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy正在招募NCT06839066研究中心II期2025-04 启动
  25. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response正在招募NCT06239727研究中心III期2024-03 启动
  26. Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma正在招募NCT06445088研究中心2024-05 启动
  27. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors正在招募NCT05956587研究中心II期2024-01 启动
  28. Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy正在招募NCT05892354研究中心不分期2023-06 启动
  29. Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial正在招募NCT05340491研究中心III期2022-04 启动
  30. PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients正在招募NCT03907826研究中心III期2020-03 启动
  31. Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma进行中,不再招募NCT06712888研究中心III期2025-02 启动
  32. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT05126719研究中心II期2023-04 启动
  33. Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)进行中,不再招募NCT05587374研究中心III期2023-08 启动
  34. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China状态不明NCT05638269研究中心2022-03 启动
  35. Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images状态不明NCT05202626研究中心2021-12 启动
  36. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT04974398研究中心III期2021-08 启动
  37. Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma已完成NCT04823468研究中心不分期2021-07 启动
  38. Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma状态不明NCT05128201研究中心II期2021-12 启动
  39. Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC状态不明NCT04557020研究中心III期2020-12 启动
  40. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)已完成NCT03924986研究中心III期2019-03 启动
  41. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer已完成NCT03581786研究中心III期2018-10 启动
  42. Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma状态不明NCT02633176研究中心III期2015-01 启动
  43. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer状态不明NCT01074021研究中心III期2009-10 启动
PubMed 以外找到的论文(未计入)74
  1. 1371P Nivolumab plus chemoradiotherapy sparing concurrent cisplatin in nasopharyngeal carcinoma (NPC): Social reintegration and patient-reported outcomes (PROs) in quality-of-life (QoL) and tolerability from a phase II PLATINUM trial2025Annals of Oncology论文
  2. 1385P A single-arm, multicenter, prospective Phase II study of tislelizumab in combination with nimotuzumab and GP induction followed by IMRT and tislelizumab plus nimotuzumab for high-risk locally advanced nasopharyngeal carcinoma2025Annals of Oncology论文
  3. 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma2025Annals of Oncology论文
  4. 707P Integrative lactate metabolism-related gene signature predicts radiosensitivity and reveals immune microenvironment features in nasopharyngeal carcinoma2025Annals of Oncology论文
  5. 708P A single-arm, multicenter, prospective phase II study of tislelizumab in combination with nimotuzumab and GP induction followed by IMRT and tislelizumab plus nimotuzumab for high-risk locally advanced nasopharyngeal carcinoma (Recent D2025Annals of Oncology论文
  6. 710P Mapping the disparity of nasopharyngeal carcinoma burden across 34 provinces in China, 1990-2040, forecasts with scenarios simulation using deep-learning algorithm2025Annals of Oncology论文
  7. A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma.2025Journal of Clinical Oncology会议摘要
  8. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Research会议摘要
  9. Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label study.2025Journal of Clinical Oncology论文
  10. Combined Liquid Biopsy of On-Treatment Plasma Epstein-Barr Virus DNA with Clinical Stage to Guide Induction Chemotherapy Cycles in Locally Advanced Nasopharyngeal Carcinoma Patients: A Multicenter Development and Validation Study2025International Journal of Radiation Oncology*Biology*Physics论文
  11. Detection of human saliva using surface-enhanced Raman spectroscopy combined with fractionation processing and machine learning for noninvasive screening of nasopharyngeal carcinoma2025Journal of Innovative Optical Health Sciences论文
  12. Development of surface-enhanced Raman spectroscopy-based biosensor for the detection of nasopharyngeal cancer-related miRNA2025Microchemical Journal论文
  13. Dosimetry of automatic non-coplanar volumetric-modulated arc therapy for nasopharyngeal carcinoma2025Radiation Medicine and Protection论文
  14. LBA35 Iza-Bren (BL-B01D1), an EGFR×HER3 bispecific antibody-drug conjugate, versus physician's choice of chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma: A randomized, open-label, multicenter, phase III, piv2025Annals of Oncology会议摘要
  15. Long-Term Outcome in Nasopharyngeal Carcinoma Following IMRT with Modified Nodal CTV Cranially Based on the International Guideline: A Single Center Experience2025International Journal of Radiation Oncology*Biology*Physics论文
  16. Metabolomics and Machine Learning Identify Novel Serum Biomarkers for Nasopharyngeal Carcinoma Diagnosis2025International Journal of Radiation Oncology*Biology*Physics论文
  17. Multicenter dosimetric consistency evaluation of IMRT and VMAT techniques based on AAPM TG119 Report and clinical cases2025Radiation Medicine and Protection论文
  18. Prognostic implications of discordant EBER and EBV DNA status in nasopharyngeal carcinoma in endemic areas.2025Journal of Clinical Oncology论文
  19. Proposal for Future Refinement of N Category in Version-Nine of AJCC/UICC TNM Staging System for Nasopharyngeal Carcinoma based on the International Consensus Recommendations for Diagnosing Extranodal Extension2025International Journal of Radiation Oncology*Biology*Physics论文
  20. Safety and Efficacy of Local Radiotherapy in De Novo Metastatic Nasopharyngeal Carcinoma with Immunochemotherapy: Systematic Review and Meta-Analysis2025International Journal of Radiation Oncology*Biology*Physics论文
  21. Systemic Treatment for Metastatic Nasopharyngeal Carcinoma2025Medical radiology书籍章节
  22. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.2025Journal of Clinical Oncology会议摘要
  23. The diagnostic value of zero echo time magnetic resonance imaging for skull base bone invasion in nasopharyngeal carcinoma2025DOAJ (DOAJ: Directory of Open Access Journals)论文
  24. Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal car2025Journal of Clinical Oncology会议摘要
  25. Validation and Development of a Refined M1 Category for Nasopharyngeal Carcinoma Based on the Ninth-Version of AJCC/UICC TNM Staging System in the Immunotherapy Era: A Multicenter Cohort Study2025International Journal of Radiation Oncology*Biology*Physics论文
  26. WITHDRAWN: 1387P Deciphering tumor heterogeneity in advanced nasopharyngeal carcinoma (stage IVA): integrative analysis of dynamic EBV-DNA fluctuations and clinical outcomes2025Annals of Oncology撤稿
  27. WITHDRAWN: 1440TiP Phase III randomized trial of tislelizumab plus gemcitabine/capecitabine(GX) versus tislelizumab plus gemcitabine/cisplatin(GP) as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma: A prospective multic2025Annals of Oncology撤稿
  28. 847O Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase III trial2024Annals of Oncology论文
  29. Abstract CT113: A dose-exploring, randomized, open-label, Phase I study for toripalimab subcutaneous injection in patients with advanced nasopharyngeal carcinoma2024Cancer Research会议摘要
  30. Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.2024Journal of Clinical Oncology会议摘要
  31. Advancing Precise Diagnosis of Nasopharyngeal Carcinoma Through Endoscopy-Based Radiomics Analysis: Transitioning from Static Imaging to Video Analysis2024SSRN Electronic Journal预印本
  32. Advancing Precise Diagnosis of Nasopharyngeal Carcinoma Through Endoscopy-Based Radiomics Analysis: Transitioning from Static Imaging to Video Analysis2024SSRN Electronic Journal预印本
  33. Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.2024Journal of Clinical Oncology会议摘要
  34. Clinical Outcomes after Dose De-Escalation for Prophylactic Nodal Irradiation in Nasopharyngeal Carcinoma: A Long-Term, Single-Center Experience2024International Journal of Radiation Oncology*Biology*Physics论文
  35. Development of the Ninth Version of the Nasopharyngeal Cancer TNM Staging System by the American Joint Committee on Cancer and Union for International Cancer Control (AJCC/UICC): Recommendations Based on a Multicenter Validation Study and C2024SSRN Electronic Journal预印本
  36. Endoscopy-Based Radiomics Analysis for Precise Diagnosis of Nasopharyngeal Carcinoma: From Static Images to Video Analysis2024SSRN Electronic Journal预印本
  37. Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).2024Journal of Clinical Oncology会议摘要
  38. Individualized Thyroid Prescriptions Based on a Novel Tolerance Dose Model for Radiation-Induced Hypothyroidism in Nasopharyngeal Carcinoma Patients2024International Journal of Radiation Oncology*Biology*Physics论文
  39. Nivolumab combined with chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): A multicenter, single-arm, phase II clinical trial.2024Journal of Clinical Oncology会议摘要
  40. Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial2024Journal of Clinical Oncology会议摘要
  41. PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma.2024Journal of Clinical Oncology会议摘要
  42. Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial.2024Journal of Clinical Oncology会议摘要
  43. The prognostic value of deep learning-based percentage of tumour-infiltrating lymphocytes in nasopharyngeal carcinoma.2024Journal of Clinical Oncology会议摘要
  44. 885P Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in nasopharyngeal carcinoma2023Annals of Oncology论文
  45. 918P SPP1-related M2 macrophage signatures predict prognosis and immunotherapy response in patients with nasopharyngeal carcinoma2023Annals of Oncology论文
  46. 919P A prognostic model of nasopharyngeal carcinoma based on 18F-FDG PET-CT radiomic parameters and clinical characteristics of patients2023Annals of Oncology论文
  47. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncology论文
  48. Delineation of clinical target volume in nasopharyngeal carcinoma2023Holistic Integrative Oncology论文
  49. Effect of machine learning-based integration develops M2 macrophage-activation genes signature on outcomes in nasopharyngeal carcinoma.2023Journal of Clinical Oncology会议摘要
  50. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2023Journal of Clinical Oncology会议摘要
  51. Improving effectiveness using nimotuzumab (NTZ) in patients with nasopharyngeal carcinoma based on the 18F-FDG PET/CT maximum standardized uptake value2023Research Square预印本
  52. Improving effectiveness using nimotuzumab in patients with nasopharyngeal carcinoma based on the 18F-FDG PET/CT maximum standardized uptake value2023Research Square预印本
  53. Prognosis-related molecular subtyping of nasopharyngeal carcinoma.2023Journal of Clinical Oncology会议摘要
  54. Refining the TNM M1 Subcategory for De Novo Metastatic Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physics论文
  55. Selectively Irradiation of the Supraclavicular Area in Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiotherapy2023International Journal of Radiation Oncology*Biology*Physics论文
  56. Sparing concurrent chemotherapy in low-risk locoregionally advanced nasopharyngeal carcinoma: A retrospective study from real-world experience2023Research Square预印本
  57. The effect of primary tumor volume on the prognosis of nasopharyngeal carcinoma in era of volumetric modulated arc therapy: a propensity score matched cohort study2023Figshare数据集
  58. Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca2022Cancer Research会议摘要
  59. Additional file 2 of Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma2022Figshare数据集
  60. Additional file 4 of RNF38 suppress growth and metastasis via ubiquitination of ACTN4 in nasopharyngeal carcinoma2022Figshare数据集
  61. Additional file 6 of RNF38 suppress growth and metastasis via ubiquitination of ACTN4 in nasopharyngeal carcinoma2022Figshare数据集
  62. Establishment of 5-hydroxymethylcytosine expression model of circulating-free DNA gene in early diagnosis of nasopharyngeal carcinoma.2022Journal of Clinical Oncology会议摘要
  63. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.2022Journal of Clinical Oncology会议摘要
  64. 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy2021Journal for ImmunoTherapy of Cancer会议摘要
  65. 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results2021Annals of Oncology论文
  66. CENPU Promotes Growth and Metastasis in Nasopharyngeal Carcinoma by Inhibiting DUSP62021Research Square预印本
  67. Dose information prediction for radiation treatment planning of nasopharyngeal carcinoma based on artificial neural networks2021International Symposium on Artificial Intelligence for Medicine Sciences (ISAIMS)会议论文
  68. Effect of Percutaneous Endoscopic Gastrostomy on Long-term Quality of Life in Patients with Locally Advanced Nasopharyngeal Carcinoma2021Research Square预印本
  69. Evaluating the Rationality of the International Guideline's Recommendations Regarding Selective Coverage of Level Ib in Node Clinical Target Volume With Nasopharyngeal Carcinoma: Results From a Real-World Series2021International Journal of Radiation Oncology*Biology*Physics论文
  70. Identifying the Optimal Candidates for the Best Utilization of Locoregional Radiation Therapy in Patients With De Novo Metastatic Nasopharyngeal Carcinoma2021International Journal of Radiation Oncology*Biology*Physics论文
  71. JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2021Journal of Clinical Oncology会议摘要
  72. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncology会议摘要
  73. Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.2021Journal of Clinical Oncology会议摘要
  74. Sequential IVIM-Parametric as a Potential Image Biomarker in Evaluating the Radiosensitivity of Human Nasopharyngeal Carcinoma Xenografts2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 32 篇,占 1.1%。

牵头论文
32
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 3320222023: 101020232024: 4420242025: 10102025

福州有 5 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2024-03
    登记号
    NCT06463834

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建省肿瘤医院福州

  2. 正在招募
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-08
    登记号
    NCT07700667

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心南京、南宁、南昌、哈尔滨、天津、太原、成都、昆明、汕头、沈阳、洛阳、石家庄、福州、西安、郑州、长春

  3. 正在招募
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    分期
    III期
    开始
    2025-03
    登记号
    NCT06644781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春

  4. 正在招募
    Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2024-03
    登记号
    NCT06342167

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心台州、天津、安阳、新乡、福州、银川

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题新辅助与综合治疗放疗分子标志物与基因
论文中的科室肿瘤内科放疗科临床试验/研究机构病理/检验科
牵头的论文32
  1. Surgical Outcomes of Robotic, Minimally Invasive, and Open Esophagectomy After Neoadjuvant Therapy: a Propensity Score-Matching Study.2026Annals of surgical oncology
  2. Long-term outcomes of S-1-based chemoradiotherapy in inoperable elderly patients with esophageal carcinoma: A multicenter, randomized, phase III clinical trial.2026Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRCT
  3. Development of a prognostic nomogram and risk stratification system for elderly patients with esophageal squamous cell carcinoma undergoing definitive radiotherapy: a multicenter retrospective analysis (3JECROG R-03 A).2025BMC cancer免费全文
  4. Selection and validation of a cell-internalizing DNA aptamer targeting esophageal squamous cell carcinoma.2025European journal of pharmacology
  5. Postoperative chemotherapy versus surgery alone in esophageal squamous cell carcinoma: A single-center propensity-matched survival analysis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  6. Neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradiotherapy in patients with borderline resectable esophageal squamous cell carcinoma.2025Journal of translational medicine免费全文
  7. The optimal number of lymph node dissections in three-field lymphadenectomy for esophageal squamous cell carcinoma: a large retrospective study.2025Langenbeck's archives of surgery免费全文
  8. A-to-I-Edited miR-1304-3p Inhibits Glycolysis and Tumor Growth of Esophageal Squamous Cell Carcinoma by Inactivating Wnt5a/ROR2 Signaling.2025Molecular carcinogenesis免费全文
  9. Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO).2025Nature communicationsRCT免费全文
  10. Validation and refinement of the 8th edition of the AJCC staging system for esophageal squamous cell carcinoma treated with definitive IMRT or chemo-IMRT: a Chinese multi-institutional retrospective study.2025Radiation oncology (London, England)免费全文
  11. A longitudinal study on the impact of cadmium exposure on quality of life in esophageal squamous cell carcinoma patients in Southern China.2025Scientific reports免费全文
  12. Constructing individualized follow-up strategies for locally advanced esophageal squamous cell carcinoma patients based on dynamic recurrence risk changes.2025Scientific reports免费全文
  13. Prospective multicenter study of camrelizumab in real-world settings for asian patients with esophageal squamous cell carcinoma.2024BMC cancer免费全文
  14. Efficacy and Safety of First-line Therapies for Advanced Unresectable Oesophageal Squamous Cell Cancer: a Systematic Review and Network Meta-analysis.2024Clinical oncology (Royal College of Radiologists (Great Britain))
  15. Comparison of neoadjuvant chemoimmunotherapy and neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a retrospective study with 3-year survival analysis.2024Journal of cancer research and clinical oncology免费全文
  16. Frequency and distribution pattern of lymph node metastasis after neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma.2024Journal of cancer research and clinical oncology免费全文
  17. Identification and validation of a prognostic signature of cuproptosis-related genes for esophageal squamous cell carcinoma.2023Aging免费全文
  18. Prognostic value of Hematoxylin and eosin staining tumor-infiltrating lymphocytes (H&E-TILs) in patients with esophageal squamous cell carcinoma treated with chemoradiotherapy.2023BMC cancer免费全文
  19. Prognostic value of pre-therapeutic nutritional risk factors in elderly patients with locally advanced esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or radiotherapy.2023BMC cancer免费全文
  20. The Prognostic Significance of Nomogram-Based Pretreatment Inflammatory Indicators in Patients With Esophageal Squamous Cell Carcinoma Receiving Intensity-Modulated Radiotherapy.2023Cancer control : journal of the Moffitt Cancer Center免费全文
  21. Pattern of relapse following three-field lymphadenectomy of esophageal carcinoma and related factors predictive of recurrence.2023Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
  22. Higher radiation dose on immune cells is associated with radiation-induced lymphopenia and worse prognosis in patients with locally advanced esophageal squamous cell carcinoma.2023Frontiers in immunology免费全文
  23. Prognostic and immunological role of cancer-associated fibroblasts-derived exosomal protein in esophageal squamous cell carcinoma.2023International immunopharmacology
  24. Clinical outcomes and toxicities of locally advanced esophageal squamous cell carcinoma patients treated with early thoracic radiation therapy after induction chemotherapy.2023International journal of clinical oncology
  25. Systemic Immune-Inflammatory Index, Tumor-Infiltrating Lymphocytes, and Clinical Outcomes in Esophageal Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy.2023Journal of immunology research免费全文
  26. Efficacy and complications of single-port thoracoscopic minimally invasive esophagectomy in esophageal squamous cell carcinoma: a single-center experience.2023Scientific reports免费全文
  27. Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China.2022Frontiers in public health免费全文
  28. Cost-effectiveness of pembrolizumab for second-line treatment of esophageal squamous cell carcinoma patients with a combined positive score of 10 or more.2022Journal of comparative effectiveness research
  29. Prognostic significance of platelet-to-albumin ratio in patients with esophageal squamous cell carcinoma receiving definitive radiotherapy.2022Scientific reports免费全文
  30. Primary gross tumor volume is prognostic and suggests treatment in upper esophageal cancer.2021BMC cancer免费全文
  31. SASS6 promotes proliferation of esophageal squamous carcinoma cells by inhibiting the p53 signaling pathway.2021Carcinogenesis
  32. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.2021Radiation oncology (London, England)免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)22
  1. A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma正在招募NCT06463834牵头方II期2024-03 启动
  2. PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma状态不明NCT05007145牵头方II期2021-08 启动
  3. SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma正在招募NCT07700667研究中心II期2026-08 启动
  4. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)正在招募NCT06644781研究中心III期2025-03 启动
  5. Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma正在招募NCT06342167研究中心II期2024-03 启动
  6. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT06010303研究中心II期2023-11 启动
  7. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma已终止NCT05461794研究中心II期2022-10 启动
  8. A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC状态不明NCT05221658研究中心II期2022-08 启动
  9. A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)进行中,不再招募NCT05094336研究中心I/II期2022-02 启动
  10. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.已完成NCT05142709研究中心2021-10 启动
  11. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
  12. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma进行中,不再招募NCT04848753研究中心III期2021-05 启动
  13. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).已终止NCT04949256研究中心III期2021-07 启动
  14. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy已完成NCT04543617研究中心III期2020-09 启动
  15. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma已完成NCT04540211研究中心III期2020-10 启动
  16. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma已完成NCT03957590研究中心III期2019-06 启动
  17. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
  18. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03430843研究中心III期2018-01 启动
  19. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03783442研究中心III期2018-12 启动
  20. PET in Guiding Cervical Lymphadenectomy (ECTOP-2003)已完成NCT03244566研究中心2018-06 启动
  21. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study已完成NCT03933449研究中心III期2016-12 启动
  22. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma状态不明NCT02611700研究中心III期2015-11 启动
PubMed 以外找到的论文(未计入)46
  1. 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma2025Annals of Oncology论文
  2. An organ-preserving strategy in patients with esophageal squamous cell carcinoma treated with immunochemotherapy.2025Journal of Clinical Oncology会议摘要
  3. Comparative Analysis of Clinical Outcomes Between Neoadjuvant Chemoimmunotherapy and Neoadjuvant Chemoradiotherapy in Patients with Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Retrospective Study2025Research Square预印本
  4. Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial2025International Journal of Radiation Oncology*Biology*Physics论文
  5. PT2.10.03 Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study2025Journal of Thoracic Oncology论文
  6. Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective exp2025Journal of Clinical Oncology会议摘要
  7. The Learning Curve of the Thoracic Phase in Single-Port Thoracoscopic Esophagectomy for Esophageal Cancer2025Research Square预印本
  8. The combination of PD-1 inhibitor with chemotherapy ± salvage chemoradiotherapy for local primary-recurrence esophageal squamous cell carcinoma after definitive chemoradiotherapy: A prospective, multicenter, single-arm clinical study (ESO-N2025Journal of Clinical Oncology论文
  9. Updated results of the ALTER-E00 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A multi-center, multi-cohort retrospective explor2025Journal of Clinical Oncology论文
  10. WITHDRAWN: 2143P Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: A multicenter, real-world, retrospective cohort study2025Annals of Oncology撤稿
  11. 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies2024Annals of Oncology论文
  12. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncology会议摘要
  13. EsccNet: A Hybrid CNN and Transformers Model for the Classification of Whole Slide Images of Esophageal Squamous Cell Carcinoma2024International Conference on Computer Engineering and Application (ICCEA)会议论文
  14. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  15. High versus standard radiation dose of definitive chemoradiotherapy combined with immunotherapy for inoperable esophageal squamous cell carcinoma: A multicenter propensity score matching analysis.2024Journal of Clinical Oncology会议摘要
  16. A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.2023Journal of Clinical Oncology会议摘要
  17. Abstract CT076: Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis2023Cancer Research会议摘要
  18. Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation2023Figshare数据集
  19. KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.2023Journal of Clinical Oncology会议摘要
  20. Long-term Outcomes of Treatment Patterns and Survival for Esophageal Squamous Cell Carcinoma Over than 70 Years: A Multicenter Analysis of 726 Cases2023Research Square预印本
  21. Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1–positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007).2023Journal of Clinical Oncology会议摘要
  22. 1207P Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study2022Annals of Oncology论文
  23. 132TiP Dose escalation of chemoradiotherapy in locally advanced esophageal squamous cell carcinoma based on positron emission tomography response: A phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)2022Annals of Oncology论文
  24. Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  25. Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  26. Additional file 3 of Characteristics and interplay of esophageal microbiota in esophageal squamous cell carcinoma2022Figshare数据集
  27. Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  28. Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  29. Association between tea consumption and quality of life in men with esophageal squamous carcinoma based on TTD model2022Research Square预印本
  30. Effectiveness of S-1–Based Chemoradiotherapy and S-1 Consolidation in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Multicenter Randomized Phase III Clinical Trial2022International Journal of Radiation Oncology*Biology*Physics论文
  31. Impact of metastatic lymph node ratio on survival in esophageal squamous cell carcinoma with celiac lymph node metastasis: A propensity score-matched analysis2022Research Square预印本
  32. Postoperative Radiotherapy Involving Tumor Bed with or without Elective Nodal Irradiation in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center, Prospective Randomized Phase II Trial2022International Journal of Radiation Oncology*Biology*Physics论文
  33. The prognostic significance of nomogram-based pretreatment inflammatory indicators in patients with esophageal squamous cell carcinoma receiving intensity- modulated radiotherapy2022Research Square预印本
  34. The prognostic significance of nomogram-based pretreatment inflammatory indicators in patients with esophageal squamous cell carcinoma receiving intensity- modulated radiotherapy2022Research Square预印本
  35. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncology论文
  36. Comparison of Two Major Staging Systems in Predicting Survival and Recommendation of Postoperative Radiotherapy Based on the 11th Japanese Classification for Esophageal Carcinoma After Curative Resection2021International Journal of Radiation Oncology*Biology*Physics论文
  37. Development of a Prognostic Nomogram and Risk Stratification System for Upper Thoracic Esophageal Squamous Cell Carcinoma2021Research Square预印本
  38. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要
  39. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncology会议摘要
  40. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Square预印本
  41. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Square预印本
  42. Molecular characterization of amplification of 11q13 region in patients with operable esophageal squamous cell carcinoma.2021Journal of Clinical Oncology会议摘要
  43. Primary Gross Tumor Volume is Prognostic and Suggests Treatment in Upper Esophageal Cancer2021Research Square预印本
  44. RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.2021Journal of Clinical Oncology会议摘要
  45. Real-world clinical effectiveness and safety of camrelizumab in esophageal squamous cell carcinoma.2021Journal of Clinical Oncology会议摘要
  46. Serum exosomal miR-4787-3p as potential lymph node metastasis and prognostic marker in esophageal squamous cell carcinoma.2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 54 篇,占 0.4%。

牵头论文
54
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 101020222023: 8820232024: 111120242025: 24242025

福州有 6 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
    分期
    II期
    开始
    2025-01
    登记号
    NCT06812039

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院;另有 2 家列出的医院为研究中心上海、天津、福州

  2. 正在招募
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-11
    登记号
    NCT07176650

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春

  3. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  4. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

  5. 即将招募
    TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
    分期
    II期
    开始
    2025-12
    登记号
    NCT07350070

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院;另有 4 家列出的医院为研究中心南宁、武汉、济南、福州、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现免疫与靶向药物
论文中的科室肿瘤内科普外/肝胆胰外科放疗科影像/核医学科
牵头的论文54
  1. Prediction of therapeutic response to transarterial chemoembolization plus systemic therapy regimen in hepatocellular carcinoma using pretreatment contrast-enhanced MRI based habitat analysis and Crossformer model.2025Abdominal radiology (New York)
  2. Mild Photothermal Bimetallic Mesoporous Nanozyme Triggers Immunogenic Cell Death and Immune Contexture Remodeling for Precision Hepatocellular Carcinoma Treatment.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. Identification of a pyroptosis-related long noncoding RNA signature for determining the prognosis and immune status of hepatocellular carcinoma patients.2025Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  4. EIF3B affects the invasion and metastasis of hepatocellular carcinoma cells via the TGFBI/MAPK/ERK pathway.2025Annals of hepatology
  5. Performance of contrast-enhanced ultrasound liver imaging reporting and data system for differentiation of patients at risk of hepatocellular carcinoma and liver metastasis.2025Annals of medicine免费全文
  6. Diagnostic and prognostic performance of serum GPC3 and PIVKA-II in AFP-negative hepatocellular carcinoma and establishment of nomogram prediction models.2025BMC cancer免费全文
  7. Discovery and validation of a novel dual-target blood test for the detection of hepatocellular carcinoma across stages from cirrhosis.2025BMC medicine免费全文
  8. Neoepitope BTLAP267L-specific TCR-T cell immunotherapy unlocks precision treatment for hepatocellular carcinoma.2025Cancer biology & medicine免费全文
  9. Assessing the Causal Effect of Circulating Protein-To-Protein Ratio on the Risk of Morbidity of Hepatocellular Carcinoma.2025Cancer medicine免费全文
  10. Automated microvascular invasion prediction of hepatocellular carcinoma via deep relation reasoning from dynamic contrast-enhanced ultrasound.2025Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
  11. Important Role of Bacterial Metabolites in Development and Adjuvant Therapy for Hepatocellular Carcinoma.2025Current oncology (Toronto, Ont.)免费全文
  12. MRI imaging features for evaluating the efficacy and prognosis of TACE combined with targeted immunotherapy in unresectable hepatocellular carcinoma.2025European journal of radiology
  13. A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving durvalumab in combination with tremelimumab.2025Frontiers in immunology免费全文
  14. Bacterial outer membrane vesicles OMV-LL for delivery of neoantigen mRNA to induce anti-HCC therapy.2025Frontiers in immunology免费全文
  15. Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification.2025Gut microbes免费全文
  16. KBTBD11 suppresses hepatocellular carcinoma by targeting ENO1-mediated glycolysis.2025Journal of translational medicine免费全文
  17. G2M-checkpoint related immune barrier structure and signature for prognosis and immunotherapy response in hepatocellular carcinoma: insights from spatial transcriptome and machine learning.2025Journal of translational medicine免费全文
  18. Identification of intratumoral bacteria correlated with hepatitis B virus (HBV) levels: a prognostic indicator for patient outcomes in hepatocellular carcinoma patients.2025Microbiology spectrum免费全文
  19. HBV-encoded circRNA-5 promotes hepatocellular carcinoma progression by regulating the miR-9-3p/Hippo signaling axis.2025Microbiology spectrum免费全文
  20. Hepatocellular carcinoma escapes immune surveillance through deceiving thymus into recalling peripheral activated CD8+ T cells.2025Neoplasia (New York, N.Y.)免费全文
  21. Hepatotoxicity of ICI monotherapy or combination therapy in HCC: A systematic review and meta-analysis.2025PloS one免费全文
  22. Immune system development-related signature predicts prognosis and sorafenib-treatment resistance of hepatocellular carcinoma by intergrating machine learning and single-cell analyses.2025Scientific reports免费全文
  23. A prediction model for moderate to severe pain in primary hepatic carcinoma after chemotherapy: a multi-center prospective case‒control study.2025Scientific reports免费全文
  24. Association of intratumoral microbiome diversity with hepatocellular carcinoma prognosis.2025mSystems免费全文
  25. Biomimetic Responsive Nanoconverters with Immune Checkpoint Blockade Plus Antiangiogenesis for Advanced Hepatocellular Carcinoma Treatment.2024ACS applied materials & interfaces
  26. Unveiling the cytotoxicity of a new gold(I) complex towards hepatocellular carcinoma by inhibiting TrxR activity.2024Acta biochimica et biophysica Sinica免费全文
  27. The Pretreatment Neutrophil-to-Lymphocyte Ratio as a Near-Term Prognostic Indicator in Patients with Locally Advanced Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy: A Propensity Score Matching Cohort Study.2024British journal of hospital medicine (London, England : 2005)
  28. IL-21- and CXCL9-engineered GPC3-specific CAR-T cells combined with PD-1 blockade enhance cytotoxic activities against hepatocellular carcinoma.2024Clinical and experimental medicine免费全文
  29. IL-12 improves the anti-HCC efficacy of dendritic cells loaded with exosomes from overexpressing Rab27a tumor cells.2024Experimental cell research
  30. Signature of immune-related metabolic genes predicts the prognosis of hepatocellular carcinoma.2024Frontiers in immunology免费全文
  31. Exosomal transfer of HCC-derived miR-17-5p downregulates NK cell function by targeting RUNX1-NKG2D axis.2024International immunopharmacology
  32. Comprehensive Analysis of the Prognostic Implications and Biological Function of HDACs in Liver Hepatocellular Carcinoma.2024International journal of medical sciences免费全文
  33. Combination of microparticles vaccine with MSI-1436 exerts a strong immune response for hepatocellular carcinoma.2024Journal of leukocyte biology
  34. Apatinib plus hepatic arterial infusion of oxaliplatin and raltitrexed for hepatocellular carcinoma with extrahepatic metastasis: phase II trial.2024Nature communications免费全文
  35. Development of an individualized model for predicting postoperative delirium in elderly patients with hepatocellular carcinoma.2024Scientific reports免费全文
  36. LI-RADS category 3, 4, and M observations: a multiple parameters diagnostic model for hepatocellular carcinoma.2023Acta radiologica (Stockholm, Sweden : 1987)
  37. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.2023BMC medical genomics免费全文
  38. Transarterial interventional therapy combined with tyrosine kinase inhibitors with or without anti-PD-1 antibodies as initial treatment for hepatocellular carcinoma with major portal vein tumor thrombosis: a single-center retrospective stud2023Cancer immunology, immunotherapy : CII免费全文
  39. Prognostic significance of three-tiered pathological classification for microvascular invasion in patients with combined hepatocellular-cholangiocarcinoma following hepatic resection.2023Cancer medicine免费全文
  40. Altered Gut Microbiota Composition and Its Potential Association in Patients with Advanced Hepatocellular Carcinoma.2023Current oncology (Toronto, Ont.)免费全文
  41. Magnetically responsive nanoplatform targeting circRNA circ_0058051 inhibits hepatocellular carcinoma progression.2023Drug delivery and translational research免费全文
  42. Altered HLA-A2-restricted TP53 epitope induces specific CTL cytotoxicity against hepatocellular carcinoma.2023European journal of immunology
  43. Hsa_circ_0001687 Function as a ceRNA to Facilitate Hepatocellular Carcinoma Progression via miR-140- 3p/FOXQ1 Axis.2023Protein and peptide letters
  44. miR-6071 inhibits hepatocellular carcinoma progression via targeting PTPN11.2022Archives of biochemistry and biophysics
  45. An Unfolded Protein Response-Related mRNA Signature Predicting the Survival and Therapeutic Effect of Hepatocellular Carcinoma.2022Combinatorial chemistry & high throughput screening
  46. Potential Diagnostic and Prognostic Values of CBX8 Expression in Liver Hepatocellular Carcinoma, Kidney Renal Clear Cell Carcinoma, and Ovarian Cancer: A Study Based on TCGA Data Mining.2022Computational and mathematical methods in medicine免费全文
  47. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.2022Frontiers in immunology免费全文
  48. Kindlin-2-miR-1258-TCF4 feedback loop promotes hepatocellular carcinoma invasion and metastasis.2022Journal of gastroenterology
  49. Comparison of Arterial Infusion Chemotherapy and Chemoembolization for Locally Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  50. Hepatic arterial infusion oxaliplatin plus raltitrexed and chemoembolization in hepatocellular carcinoma with portal vein invasion: A propensity score-matching cohort study.2022Journal of surgical oncology
  51. A simplified model for prophylactic transarterial chemoembolization after resection for patients with hepatocellular carcinoma.2022PloS one免费全文
  52. Systematic review of adjuvant external beam radiotherapy for hepatocellular carcinoma following radical hepatectomy.2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  53. Development and validation of nomogram to predict very early recurrence of combined hepatocellular-cholangiocarcinoma after hepatic resection: a multi-institutional study.2022World journal of surgical oncology免费全文
  54. Dual inhibition of reactive oxygen species and spleen tyrosine kinase as a therapeutic strategy in liver fibrosis.2021Free radical biology & medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)18
  1. Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma状态不明NCT06061445牵头方不分期2024-01 启动
  2. TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension即将招募NCT07350070研究中心II期2025-12 启动
  3. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  4. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07176650研究中心I期2025-11 启动
  5. HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence正在招募NCT06812039研究中心II期2025-01 启动
  6. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  7. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere进行中,不再招募NCT06900543研究中心III期2025-04 启动
  8. PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma已完成NCT05864105研究中心II期2022-04 启动
  9. A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT05432492研究中心II期2022-08 启动
  10. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma进行中,不再招募NCT04712643研究中心III期2021-03 启动
  11. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC已完成NCT04948697研究中心II期2021-08 启动
  12. Application Value of CEUS Li-RADS in Hepatic Focal Lesions in Patients With Non-high Risk Factors for HCC状态不明NCT04920214研究中心2021-01 启动
  13. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)已终止NCT04246177研究中心III期2020-05 启动
  14. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  15. A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor进行中,不再招募NCT04008797研究中心I/II期2019-07 启动
  16. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动
  17. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)已完成NCT03867084研究中心III期2019-05 启动
  18. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 38 篇,占 0.4%。

牵头论文
38
2021–2025 年
牵头试验
16
任何状态,ClinicalTrials.gov
牵头的开放试验
4
正在或即将招募
作为研究中心的开放试验
9
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 3320222023: 8820232024: 6620242025: 14142025

福州有 6 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 13

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
    分期
    III期
    开始
    2025-06
    登记号
    NCT06793917

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:福建省肿瘤医院福州

  2. 正在招募
    Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical Trial
    分期
    不分期
    开始
    2025-01
    登记号
    NCT07142122

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建省肿瘤医院福州

  3. 正在招募
    Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
    分期
    I/II期
    开始
    2023-02
    登记号
    NCT05319639

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建省肿瘤医院福州

  4. 正在招募
    Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
    分期
    II/III期
    开始
    2023-05
    登记号
    NCT05699655

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建省肿瘤医院福州

  5. 正在招募
    A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
    分期
    II/III期
    开始
    2026-03
    登记号
    NCT07221149

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、南宁、广州、福州

  6. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  7. 正在招募
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    分期
    III期
    开始
    2025-02
    登记号
    NCT06731478

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、厦门、合肥、哈尔滨、天津、太原、常州、徐州、杭州、武汉、沈阳、济南、福州、苏州、西安、郑州、银川

  8. 正在招募
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    分期
    未注明
    开始
    2025-02
    登记号
    NCT06846996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春

  9. 正在招募
    A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
    分期
    III期
    开始
    2025-08
    登记号
    NCT07023315

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、哈尔滨、石家庄、福州

  10. 正在招募
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    分期
    III期
    开始
    2024-11
    登记号
    NCT06532006

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、石家庄、福州、蚌埠、郑州、重庆、银川、长春、长沙、青岛

  11. 正在招募
    A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
    分期
    I期
    开始
    2024-07
    登记号
    NCT07923214

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、成都、福州

  12. 正在招募
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    分期
    未注明
    开始
    2023-09
    登记号
    NCT06035250

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南宁、天津、广州、昆明、沈阳、福州、苏州、郑州、长沙、青岛

  13. 正在招募
    Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    II期
    开始
    2023-11
    登记号
    NCT06155383

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心北京、厦门、哈尔滨、广州、成都、昆明、济南、福州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期化疗与综合治疗营养与康复
论文中的科室肿瘤内科病理/检验科影像/核医学科放疗科
牵头的论文38
  1. Integrative Multi-Omics Analysis Uncovers Immunological Phenotypes Predictive of Combinatorial Immunotherapy Response in Gastric Cancer.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Application of gastric ultrasound in evaluating the efficacy of preoperative neoadjuvant therapy for gastric carcinoma.2026European journal of radiology
  3. Solasonine Restores Sensitivity of Gastric Cancer to NK Cells through DNA Demethylation of MICA.2025Advanced biology
  4. Erythrocyte lifespan for predicting moderate and severe anemia in advanced gastric cancer patients post-anti-tumor therapeutics: a prospective study.2025BMC cancer免费全文
  5. CircCHAF1A induced cellular senescence by enhancing the stability of p21 to suppress gastric cancer progression.2025Biochemical pharmacology
  6. Short- and Mid-Term Outcomes of Proximal Gastrectomy With Double-Tract Reconstruction Versus Total Gastrectomy in Early-Stage Proximal Gastric Cancer.2025Cancer medicine免费全文
  7. Plasma immune proteome-based risk score predicts survival in advanced gastric cancer treated with PD-1 inhibitors and chemotherapy.2025Frontiers in immunology免费全文
  8. Neoadjuvant chemotherapy combined with antiangiogenic therapy and immune checkpoint inhibitors for the treatment of locally advanced gastric cancer: a real - world retrospective cohort study.2025Frontiers in immunology免费全文
  9. Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer.2025Frontiers in public health免费全文
  10. SNRPB promotes gastric cancer progression via the ECM receptor signaling pathway.2025Gene
  11. Development of antibody-drug conjugates in gastric cancer: an overview of clinical trials from 2005 to 2025.2025International journal of surgery (London, England)免费全文
  12. Deep learning-based prediction of HER2 status and trastuzumab treatment efficacy of gastric adenocarcinoma based on morphological features.2025Journal of translational medicine免费全文
  13. Prognostic stratification of gastric cancer patients by intratumoral microbiota-mediated tumor immune microenvironment.2025Microbial pathogenesis
  14. Global Leadership Initiative on Malnutrition criteria: Clinical benefits for patients with gastric cancer.2025Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
  15. Modified RECIST submodels and ordinal regression model predict neoadjuvant chemoimmunotherapy response in locally advanced gastric cancer​​.2025Scientific reports免费全文
  16. miRNA-214-3p targets BNIP3 to affect autophagy and thus drive gastric cancer progression.2025The Journal of toxicological sciences
  17. Investigation of the association between the Toll-like receptor 1 rs4833095 variation and gastric adenocarcinoma recurrence.2024Annals of human genetics
  18. Identification of prognostic signatures in remnant gastric cancer through an interpretable risk model based on machine learning: a multicenter cohort study.2024BMC cancer免费全文
  19. Phase I trial of apatinib and paclitaxel+oxaliplatin+5-FU/levoleucovorin for treatment-naïve advanced gastric cancer.2024Cancer science免费全文
  20. Characterization of the Prognosis and Tumor Microenvironment of Cellular Senescence-related Genes through scRNA-seq and Bulk RNA-seq Analysis in GC.2024Recent patents on anti-cancer drug discovery
  21. Short-term outcomes of distal gastrectomy versus total gastrectomy for gastric cancer under enhanced recovery after surgery: a propensity score-matched analysis.2024Scientific reports免费全文
  22. Whole-volume histogram analysis of spectral-computed tomography iodine maps characterizes HER2 expression in gastric cancer.2024World journal of gastroenterology免费全文
  23. Using less annotation workload to establish a pathological auxiliary diagnosis system for gastric cancer.2023Cell reports. Medicine免费全文
  24. Melatonin inhibited the progression of gastric cancer induced by Bisphenol S via regulating the estrogen receptor 1.2023Ecotoxicology and environmental safety
  25. Collagen-related gene expression level predicts the prognosis and immune therapy response.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  26. Impact of PIWIL1 Single Nucleotide Polymorphisms on Gastric Cancer Risk in a Chinese Population.2023Genetic testing and molecular biomarkers
  27. Long-term health-related quality of life in patients with gastric cancer after total or distal gastrectomy: a propensity score-matched cohort study.2023International journal of surgery (London, England)免费全文
  28. The Influence of Group No.8p Lymph Node Dissection on the Prognosis of Advanced Gastric Cancer.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  29. Clinicopathologic features and prognosis of 71 patients with gastric cancer and disseminated intravascular coagulation.2023PeerJ免费全文
  30. RNU12 inhibits gastric cancer progression via sponging miR-575 and targeting BLID.2023Scientific reports免费全文
  31. Interleukin-15 and chemokine ligand 19 enhance cytotoxic effects of chimeric antigen receptor T cells using zebrafish xenograft model of gastric cancer.2022Frontiers in immunology免费全文
  32. Intraperitoneal infusion of recombinant human endostatin improves prognosis in gastric cancer ascites.2022Future oncology (London, England)
  33. Solasonine induces apoptosis of the SGC-7901 human gastric cancer cell line in vitro via the mitochondria-mediated pathway.2022Journal of cellular and molecular medicine免费全文
  34. Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer.2021BMC cancer免费全文
  35. Prognostic value of preoperative body mass index for diabetic patients with non-metastasis gastric cancer: a single center experience.2021BMC surgery免费全文
  36. Residue substitution enhances the immunogenicity of neoepitopes from gastric cancers.2021Cancer biology & medicine免费全文
  37. Identification of Potential Biomarkers Associated with Prognosis in Gastric Cancer via Bioinformatics Analysis.2021Medical science monitor : international medical journal of experimental and clinical research免费全文
  38. Failure of enhanced recovery programs after laparoscopic radical gastrectomy: a single-center retrospective study.2021Surgical endoscopy
中文论文(未计入)4
  1. [Theory and practice on mesentery margin in vessel-oriented complete mesentery resection of gastric cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Prognostic values of stromal tumor-infiltrating lymphocytes and lymphocyte-activation gene-3 in advanced gastric adenocarcinoma].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  3. [Identification of characteristic methylation sites in gastric cancer using genomics-based machine learning].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
  4. [Safety and short-term efficacy of apatinib combined with oxaliplatin and S-1 in the conversion treatment for gastric cancer with peritoneal metastasis].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)48
  1. Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma正在招募NCT06793917牵头方III期2025-06 启动
  2. Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical Trial正在招募NCT07142122牵头方不分期2025-01 启动
  3. Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab正在招募NCT05319639牵头方I/II期2023-02 启动
  4. Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer正在招募NCT05699655牵头方II/III期2023-05 启动
  5. A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors进行中,不再招募NCT07104877牵头方不分期2024-04 启动
  6. Study of FMT Combined With Nivolumab in Gastric Cancer已撤回NCT05001360牵头方不分期2021-10 启动
  7. Short-term Outcomes of SILS+1 Versus CLS for Distal Gastric Cancer状态不明NCT05035446牵头方III期2021-10 启动
  8. Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer已完成NCT05223088牵头方II期2021-10 启动
  9. PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer状态不明NCT04174339牵头方不分期2019-12 启动
  10. Study of the Apatinib Combine With POF Versus POF in Gastric Cancer状态不明NCT04121039牵头方II期2019-12 启动
  11. A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer状态不明NCT03788226牵头方III期2019-02 启动
  12. Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer状态不明NCT03137004牵头方II期2017-06 启动
  13. Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA状态不明NCT03030937牵头方II期2017-02 启动
  14. mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA状态不明NCT03045770牵头方不分期2017-02 启动
  15. Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer状态不明NCT02697838牵头方II期2016-08 启动
  16. POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC已完成NCT02845908牵头方II期2015-11 启动
  17. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  18. A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)正在招募NCT07221149研究中心II/III期2026-03 启动
  19. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer正在招募NCT06731478研究中心III期2025-02 启动
  20. A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma正在招募NCT07023315研究中心III期2025-08 启动
  21. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China正在招募NCT06846996研究中心2025-02 启动
  22. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer正在招募NCT06532006研究中心III期2024-11 启动
  23. A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors正在招募NCT07923214研究中心I期2024-07 启动
  24. Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT06155383研究中心II期2023-11 启动
  25. AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy正在招募NCT06035250研究中心2023-09 启动
  26. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)进行中,不再招募NCT06356311研究中心III期2024-05 启动
  27. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China状态不明NCT05638269研究中心2022-03 启动
  28. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  29. A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)进行中,不再招募NCT05094336研究中心I/II期2022-02 启动
  30. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  31. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  32. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  33. Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)进行中,不再招募NCT04704934研究中心III期2021-05 启动
  34. A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma已终止NCT04718402研究中心I期2021-03 启动
  35. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  36. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations状态不明NCT05019794研究中心II期2020-05 启动
  37. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension已完成NCT04882241研究中心III期2020-07 启动
  38. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  39. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  40. Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer已完成NCT04082364研究中心II/III期2019-09 启动
  41. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)已完成NCT03675737研究中心III期2018-11 启动
  42. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer已完成NCT03694522研究中心II期2018-09 启动
  43. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)已完成NCT03615326研究中心III期2018-10 启动
  44. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension已撤回NCT04859582研究中心III期2018-11 启动
  45. Incidence of Pancreatic Fistula After Radical Gastrectomy状态不明NCT03391687研究中心2017-12 启动
  46. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)状态不明NCT02461407研究中心II/III期2015-06 启动
  47. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)状态不明NCT01609309研究中心III期2012-09 启动
  48. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer已终止NCT01641939研究中心II/III期2012-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

福州有 1 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科
牵头的论文1
  1. 2 years is a reasonable age cut-off level for prognostic assessment of children with hepatoblastoma.2023European review for medical and pharmacological sciences

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

福州有 6 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
中文论文(未计入)1
  1. [Optimal duration of preoperative imatinib therapy in locally advanced gastrointestinal stromal tumors].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
早期论文(2016–2020 年)1
  1. [The value of (18)F-FDG PET-CT imaging in predicting the malignant potential of GIST].2017Zhonghua zhong liu za zhi [Chinese journal of oncology]

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

福州有 9 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科
牵头的论文1
  1. Risk factors and novel predictive models for metastatic neuroblastoma in children.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

福建省肿瘤医院

Fujian Cancer Hospital

福州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Fujian Provincial Cancer Hospital; Fujian Medical University Cancer Hospital; Fujian Cancer Hospital & Fujian Medical University Cancer Hospital; Fujian Medical University Cancer Hospital & Fujian Cancer Hospital; Fujian Cancer Hospital and Fujian Medical University Cancer Hospital; Fujian Medical University Cancer Hospital and Fujian Cancer Hospital; Fujian Cancer Hospital &; Fujian Cancer Hospital & Affiliated Cancer Hospital

提出更正下载数据